Genmab A/SNASDAQ:GMAB
- LAST PRICE28.1020
- TODAY'S CHANGE (%)0.1120 (0.4001%)
- Bid / Lots28.1000/ 2
- Ask / Lots28.1200/ 3
- Open / Previous Close28.1300 / 27.9900
- Day Range
- 52 Week Range
- Volume298,187
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GMAB |
|---|---|---|
| 09:32 ET | 3225 | 28.15 |
| 09:34 ET | 200 | 28.115 |
| 09:36 ET | 6620 | 28.175 |
| 09:38 ET | 952 | 28.1775 |
| 09:39 ET | 5361 | 28.22 |
| 09:41 ET | 1600 | 28.215 |
| 09:43 ET | 2220 | 28.26 |
| 09:45 ET | 8238 | 28.33 |
| 09:48 ET | 1627 | 28.33 |
| 09:50 ET | 1500 | 28.3 |
| 09:52 ET | 731 | 28.315 |
| 09:54 ET | 2371 | 28.33 |
| 09:56 ET | 500 | 28.32 |
| 09:57 ET | 1870 | 28.32 |
| 09:59 ET | 900 | 28.32 |
| 10:01 ET | 400 | 28.29 |
| 10:03 ET | 1200 | 28.31 |
| 10:06 ET | 162 | 28.33 |
| 10:08 ET | 1538 | 28.35 |
| 10:10 ET | 255 | 28.36 |
| 10:12 ET | 1009 | 28.32 |
| 10:14 ET | 1226 | 28.31 |
| 10:15 ET | 4951 | 28.33 |
| 10:17 ET | 1292 | 28.33 |
| 10:19 ET | 921 | 28.34 |
| 10:21 ET | 1708 | 28.3879 |
| 10:24 ET | 1200 | 28.39 |
| 10:26 ET | 5517 | 28.395 |
| 10:28 ET | 2901 | 28.41 |
| 10:30 ET | 955 | 28.42 |
| 10:32 ET | 2000 | 28.38 |
| 10:33 ET | 1190 | 28.39 |
| 10:35 ET | 1241 | 28.35 |
| 10:37 ET | 1977 | 28.3568 |
| 10:39 ET | 1768 | 28.39 |
| 10:42 ET | 10778 | 28.38 |
| 10:44 ET | 200 | 28.36 |
| 10:46 ET | 5009 | 28.36 |
| 10:48 ET | 5623 | 28.36 |
| 10:50 ET | 400 | 28.29 |
| 10:51 ET | 1161 | 28.26 |
| 10:53 ET | 3416 | 28.3 |
| 10:57 ET | 9700 | 28.36 |
| 11:00 ET | 34673 | 28.21 |
| 11:02 ET | 1195 | 28.2 |
| 11:04 ET | 200 | 28.19 |
| 11:06 ET | 2655 | 28.18 |
| 11:08 ET | 3219 | 28.19 |
| 11:09 ET | 227 | 28.17 |
| 11:11 ET | 900 | 28.19 |
| 11:13 ET | 1123 | 28.21 |
| 11:15 ET | 1660 | 28.19 |
| 11:18 ET | 600 | 28.13 |
| 11:20 ET | 1000 | 28.12 |
| 11:22 ET | 2861 | 28.09 |
| 11:24 ET | 214 | 28.09 |
| 11:26 ET | 488 | 28.06 |
| 11:27 ET | 213 | 28.06 |
| 11:29 ET | 1989 | 28.07 |
| 11:31 ET | 661 | 28.075 |
| 11:33 ET | 338 | 28.075 |
| 11:36 ET | 613 | 28.075 |
| 11:38 ET | 900 | 28.05 |
| 11:40 ET | 714 | 28.06 |
| 11:42 ET | 400 | 28.05 |
| 11:44 ET | 900 | 28.05 |
| 11:45 ET | 1200 | 28.06 |
| 11:47 ET | 317 | 28.05 |
| 11:49 ET | 300 | 28.05 |
| 11:51 ET | 200 | 28.05 |
| 11:54 ET | 4344 | 28.07 |
| 11:56 ET | 400 | 28.06 |
| 11:58 ET | 195 | 28.055 |
| 12:00 ET | 610 | 28.0582 |
| 12:02 ET | 1565 | 28.01 |
| 12:03 ET | 800 | 28.01 |
| 12:05 ET | 100 | 28 |
| 12:07 ET | 1662 | 28.02 |
| 12:09 ET | 299 | 28.02 |
| 12:12 ET | 300 | 28.01 |
| 12:14 ET | 801 | 28.0104 |
| 12:16 ET | 500 | 28.01 |
| 12:18 ET | 1580 | 28.01 |
| 12:20 ET | 2370 | 28 |
| 12:21 ET | 1300 | 28 |
| 12:23 ET | 440 | 27.99 |
| 12:25 ET | 1497 | 28 |
| 12:27 ET | 640 | 28.01 |
| 12:30 ET | 822 | 28.01 |
| 12:32 ET | 1035 | 28.01 |
| 12:34 ET | 100 | 28 |
| 12:36 ET | 780 | 28 |
| 12:38 ET | 800 | 28.01 |
| 12:39 ET | 1903 | 28.0003 |
| 12:41 ET | 1617 | 28.0397 |
| 12:43 ET | 300 | 28.04 |
| 12:48 ET | 200 | 28.02 |
| 12:50 ET | 100 | 28.02 |
| 12:52 ET | 2939 | 28 |
| 12:54 ET | 100 | 28 |
| 12:56 ET | 300 | 27.99 |
| 12:57 ET | 404 | 28 |
| 12:59 ET | 1100 | 28 |
| 01:01 ET | 333 | 28.01 |
| 01:03 ET | 200 | 28.03 |
| 01:06 ET | 300 | 28.03 |
| 01:08 ET | 216 | 28.01 |
| 01:10 ET | 874 | 28.01 |
| 01:12 ET | 1705 | 28.01 |
| 01:14 ET | 600 | 28.01 |
| 01:15 ET | 110 | 28.01 |
| 01:17 ET | 100 | 28.02 |
| 01:19 ET | 1023 | 28.05 |
| 01:24 ET | 800 | 28.05 |
| 01:26 ET | 301 | 28.06 |
| 01:30 ET | 500 | 28.08 |
| 01:32 ET | 100 | 28.075 |
| 01:33 ET | 100 | 28.075 |
| 01:35 ET | 436 | 28.06 |
| 01:37 ET | 1785 | 28.09 |
| 01:39 ET | 650 | 28.0821 |
| 01:42 ET | 100 | 28.1 |
| 01:44 ET | 1138 | 28.08 |
| 01:46 ET | 600 | 28.1 |
| 01:48 ET | 100 | 28.11 |
| 01:50 ET | 489 | 28.08 |
| 01:51 ET | 200 | 28.08 |
| 01:53 ET | 749 | 28.08 |
| 01:55 ET | 200 | 28.075 |
| 01:57 ET | 1500 | 28.05 |
| 02:00 ET | 100 | 28.06 |
| 02:02 ET | 200 | 28.06 |
| 02:04 ET | 1083 | 28.08 |
| 02:06 ET | 2928 | 28.07 |
| 02:08 ET | 100 | 28.07 |
| 02:09 ET | 1245 | 28.0898 |
| 02:11 ET | 404 | 28.09 |
| 02:13 ET | 724 | 28.11 |
| 02:15 ET | 420 | 28.11 |
| 02:18 ET | 8230 | 28.09 |
| 02:20 ET | 972 | 28.1097 |
| 02:22 ET | 500 | 28.1 |
| 02:24 ET | 400 | 28.11 |
| 02:26 ET | 1200 | 28.123 |
| 02:29 ET | 331 | 28.1298 |
| 02:31 ET | 1278 | 28.1285 |
| 02:33 ET | 350 | 28.125 |
| 02:36 ET | 1392 | 28.125 |
| 02:38 ET | 773 | 28.11 |
| 02:40 ET | 100 | 28.1 |
| 02:42 ET | 860 | 28.102 |
Today
DJ Genmab A/S Stock Rises Friday, Underperforms Market, from 2 hours ago by Dow Jones
2 hours ago by Dow Jones
Yesterday
DJ Genmab A/S Stock Rises Thursday, Underperforms Market, from 12:01PM ET on Thursday May 30, 2024 by Dow Jones
12:01PM ET on Thursday May 30, 2024 by Dow Jones
May 23, 2024
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, from 5:00PM ET on Thursday May 23, 2024 by Dow Jones
5:00PM ET on Thursday May 23, 2024 by Dow JonesDJ Genmab A/S Stock Falls Thursday, Underperforms Market, from 12:01PM ET on Thursday May 23, 2024 by Dow Jones
12:01PM ET on Thursday May 23, 2024 by Dow Jones
May 22, 2024
DJ Genmab A/S Stock Rises Wednesday, Outperforms Market, from 12:01PM ET on Wednesday May 22, 2024 by Dow Jones
12:01PM ET on Wednesday May 22, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Genmab A/S | 18.5B | 23.4x | +22.71% |
Denali Therapeutics Inc | 2.6B | -19.2x | --- |
Amicus Therapeutics Inc | 2.9B | -20.0x | --- |
MorphoSys AG | 2.8B | -5.4x | --- |
TG Therapeutics Inc | 2.6B | 74.4x | --- |
Galapagos NV | 1.8B | 54.8x | --- |
Company Information
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Contact Information
- Headquarters
- Kalvebod Brygge 43KOEBENHAVN V, Denmark 1560
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Deirdre Connelly
- President, Chief Executive Officer
- Jan Van De Winkel
- Independent Deputy Chairman of the Board
- Pernille Erenbjerg
- Chief Financial Officer, Executive Vice President
- Anthony Pagano
- Chief Operating Officer, Executive Vice President
- Anthony Mancini
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $18.5B |
|---|---|
Revenue (TTM) | $2.6B |
Shares Outstanding | 661.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.99 |
EPS | $1.20 |
Book Value | $7.03 |
P/E Ratio | 23.4x |
Price/Sales (TTM) | 7.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | 32.00% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
